Accueil › Cancer du foie (carcinome hépatocellulaire) › New York › New York City
Essais cliniques pour Cancer du foie (carcinome hépatocellulaire) à New York City, NY
24 études pour Cancer du foie (carcinome hépatocellulaire) recherchent des participants dans et autour de New York City (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
A Study of ZW251 in Participants With Advanced Solid Tumors
Recrutement en coursPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Recrutement en coursPhase 1
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
Recrutement en coursPhase 1/2
- Research Facility, New York
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Recrutement en coursPhase 1
- Columbia University Irving Medical Center, New York
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Recrutement en coursPhase 1/2
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Recrutement en coursÉtude observationnelle
- NYU Langone Health, New York
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- et 1 autres
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Recrutement en coursPhase 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Recrutement en coursPhase 1
- New York Cancer & Blood Specialists, New York
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Recrutement en coursPhase 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Recrutement en coursPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Recrutement en coursPhase 3
- Mount Sinai Hospital, New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Recrutement en coursPhase 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
Recrutement en coursPhase 4
- Icahn School of Medicine at Mount Sinai, New York
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Recrutement en coursPhase 2
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Recrutement en coursPhase 1
- Clinical Trial Site, New York
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Recrutement en cours
- VA NY Harbor Healthcare System, New York, NY, New York
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Recrutement en coursPhase 1
- Memorial Sloan Kettering Cancer Center, New York
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Recrutement en coursPhase 2
- USA04-0, New York
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Recrutement en coursPhase 1/2
- Memorial Sloan Kettering Cancer Center - New York, New York
HOPE Against Cancer Recurrence in HCC
Recrutement en coursPhase 4
- Rutgers New Jersey Medical School (New York), New York
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Recrutement en coursPhase 1/2
- Research Site 107, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Recrutement en coursÉtude observationnelle
- Massive Bio SYNERGY-AI site, New York
The Dragon PLC Trial (DRAGON-PLC)
Recrutement en cours
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Recrutement en coursPhase 1/2
- Memorial Sloan-Kettering Cancer Center, New York
Essais pour Cancer du foie (carcinome hépatocellulaire) dans d'autres villes
- Houston, TX31 études
- Dallas, TX19 études
- Los Angeles, CA19 études
- Boston, MA18 études
- Cleveland, OH18 études
- Chicago, IL16 études
- Philadelphia, PA16 études
- Pittsburgh, PA15 études
- San Francisco, CA14 études
- Orange, CA14 études
- Jacksonville, FL14 études
- San Antonio, TX13 études
Autres études à New York City
- Cancer du sein136 études
- Cancer du poumon non à petites cellules121 études
- Cancer (tous types)109 études
- Cancer de la prostate103 études
- Cancer métastatique93 études
- Cancer colorectal78 études
- Cancer de l'ovaire69 études
- Cancer du poumon60 études
- Myélome multiple60 études
- Cancer du pancréas60 études
- Cancer de l'endomètre52 études
- Leucémie aiguë myéloïde51 études
Source : ClinicalTrials.gov, données récupérées le 6 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.